Identification and functional characterization of the novel human ether-a-go-go-related gene (hERG) R744P mutant associated with hereditary long QT syndrome 2

Biochemical and Biophysical Research Communications

Volumn 418, Issue 4, 2012, Pages 830-835

  Aidery, Parwez ^a   Kisselbach, Jana ^a   Gaspar, Harald ^a   Baldea, Ioana ^a   Schweizer, Patrick A ^a   Becker, Rüdiger ^a   Katus, Hugo A ^a   Thomas, Dierk ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cardiac electrophysiology; HERG (Kv11.1); I Kr current; Long QT syndrome; Mutation; Sudden cardiac death

Indexed keywords

POTASSIUM CHANNEL HERG;

ANIMAL CELL; ARTICLE; AUDITORY STIMULATION; CASE REPORT; CELL MIGRATION; ELECTROPHYSIOLOGY; FEMALE; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC IDENTIFICATION; HEART DEATH; HUMAN; IN VITRO STUDY; LONG QT SYNDROME; MISSENSE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SYNCOPE; WESTERN BLOTTING; XENOPUS LAEVIS;

AMINO ACID SUBSTITUTION; ANIMALS; ARGININE; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HUMANS; LONG QT SYNDROME; MUTATION, MISSENSE; PATCH-CLAMP TECHNIQUES; PEDIGREE; PROLINE; XENOPUS LAEVIS;

SYNCOPE; XENOPUS LAEVIS;

EID: 84863403879     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.01.118     Document Type: Article

References (32)

1. Moss A.J. Long QT syndrome. JAMA 2003, 289:2041-2044.
2. Hedley P.L., Jorgensen P., Schlamowitz S., Wangari R., Moolman-Smook J., Brink P.A., Kanters J.K., Corfield V.A., Christiansen M. The genetic basis of long QT and short QT syndromes: a mutation update. Hum. Mutat. 2009, 30:1485-1511.
3. Ficker E., Thomas D., Viswanathan P.C., Dennis A.T., Priori S.G., Napolitano C., Memmi M., Wible B.A., Kaufman E.S., Iyengar S., Schwartz P.J., Rudy Y., Brown A.M. Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H1748-H1756.
4. Moss A.J., Zareba W., Kaufman E.S., Gartman E., Peterson D.R., Benhorin J., Towbin J.A., Keating M.T., Priori S.G., Schwartz P.J., Vincent G.M., Robinson J.L., Andrews M.L., Feng C., Hall W.J., Medina A., Zhang L., Wang Z. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 2002, 105:794-799.
5. Thomas D., Kiehn J., Katus H.A., Karle C.A. Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. Cardiovasc. Res. 2003, 60:235-241.
6. Brugada R., Hong K., Dumaine R., Cordeiro J., Gaita F., Borggrefe M., Menendez T.M., Brugada J., Pollevick G.D., Wolpert C., Burashnikov E., Matsuo K., Wu Y.S., Guerchicoff A., Bianchi F., Giustetto C., Schimpf R., Brugada P., Antzelevitch C. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004, 109:30-35.
7. Thomas D., Karle C.A., Kiehn J. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr. Pharm. Des. 2006, 12:2271-2283.
8. Kiehn J., Thomas D., Karle C.A., Schöls W., Kübler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch. Pharmacol. 1999, 359:212-219.
9. Thomas D., Kathöfer S., Zhang W., Wu K., Wimmer A.B., Zitron E., Kreye V.A.W., Katus H.A., Schoels W., Karle C.A., Kiehn J. Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels. Br. J. Pharmacol. 2003, 140:996-1002.
10. Kathofer S., Thomas D., Karle C.A. The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc. Drug Rev. 2005, 23:217-230.
11. Thomas D., Gut B., Karsai S., Wimmer A.B., Wu K., Wendt-Nordahl G., Zhang W., Kathöfer S., Schoels W., Katus H.A., Kiehn J., Karle C.A. Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. Naunyn Schmiedebergs Arch. Pharmacol. 2003, 368:41-48.
12. Thomas D., Wimmer A.B., Wu K., Hammerling B.C., Ficker E.K., Kuryshev Y.A., Kiehn J., Katus H.A., Schoels W., Karle C.A. Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369:462-472.
13. Staudacher I., Schweizer P.A., Katus H.A., Thomas D. HERG: protein trafficking and potential for therapy and drug side effects. Curr. Opin. Drug Discov. Devel. 2010, 13:23-30.
14. Staudacher I., Wang L., Wan X., Obers S., Wenzel W., Tristram F., Koschny R., Staudacher K., Kisselbach J., Koelsch P., Schweizer P.A., Katus H.A., Ficker E., Thomas D. HERG K+ channel-associated cardiac effects of the antidepressant drug desipramine. Naunyn Schmiedebergs Arch. Pharmacol. 2011, 383:119-139.
15. Obers S., Staudacher I., Ficker E., Dennis A., Koschny R., Erdal H., Bloehs R., Kisselbach J., Karle C.A., Schweizer P.A., Katus H.A., Thomas D. Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. Naunyn Schmiedebergs Arch. Pharmacol. 2010, 381:385-400.
16. Jehle J., Schweizer P.A., Katus H.A., Thomas D. Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis. 2011, 2:e193.
17. Cui J., Melman Y., Palma E., Fishman G.I., McDonald T.V. Cyclic AMP regulates the HERG K(+) channel by dual pathways. Curr. Biol. 2000, 10:671-674.
18. Cui J., Kagan A., Qin D., Mathew J., Melman Y.F., McDonald T.V. Analysis of the cyclic nucleotide binding domain of the HERG potassium channel and interactions with KCNE2. J. Biol. Chem. 2001, 276:17244-17251.
19. Thomas D., Kiehn J., Katus H.A., Karle C.A. Adrenergic regulation of the rapid component of the cardiac delayed rectifier potassium current, I(Kr), and the underlying hERG ion channel. Basic Res. Cardiol. 2004, 99:279-287.
20. Akhavan A., Atanasiu R., Noguchi T., Han W., Holder N., Shrier A. Identification of the cyclic-nucleotide-binding domain as a conserved determinant of ion-channel cell-surface localization. J. Cell Sci. 2005, 118:2803-2812.
21. Hsueh C.H., Chen W.P., Lin J.L., Liu Y.B., Su M.J., Lai L.P. Functional studies on three novel HCNH2 mutations in Taiwan: identification of distinct mechanisms of channel defect and dissociation between glycosylation defect and assembly defect. Biochem. Biophys. Res. Commun. 2008, 373:572-578.
22. Thomas D., Plant L.D., Wilkens C.M., McCrossan Z.A., Goldstein S.A.N. Alternative translation initiation in rat brain yields K2P2.1 potassium channels permeable to sodium. Neuron 2008, 58:859-870.
23. Thomas D., Wimmer A.B., Karle C.A., Licka M., Alter M., Khalil M., Ulmer H.E., Kathofer S., Kiehn J., Katus H.A., Schoels W., Koenen M., Zehelein J. Dominant-negative I(Ks) suppression by KCNQ1-DeltaF339 potassium channels linked to Romano-Ward syndrome. Cardiovasc. Res. 2005, 67:487-497.
24. Kiehn J., Karle C., Thomas D., Yao X., Brachmann J., Kübler W. HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways. J. Biol. Chem. 1998, 273:25285-25291.
25. Thomas D., Zhang W., Karle C.A., Kathöfer S., Schöls W., Kübler W., Kiehn J. Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A. J. Biol. Chem. 1999, 274:27457-27462.
26. Staudacher K., Baldea I., Kisselbach J., Staudacher I., Rahm A.K., Schweizer P.A., Becker R., Katus H.A., Thomas D. Alternative splicing determines mRNA translation initiation and function of human K(2P)10.1 K+ channels. J. Physiol. 2011, 589:3709-3720.
27. Schwartz P.J., Priori S.G., Spazzolini C., Moss A.J., Vincent G.M., Napolitano C., Denjoy I., Guicheney P., Breithardt G., Keating M.T., Towbin J.A., Beggs A.H., Brink P., Wilde A.A., Toivonen L., Zareba W., Robinson J.L., Timothy K.W., Corfield V., Wattanasirichaigoon D., Corbett C., Haverkamp W., Schulze-Bahr E., Lehmann M.H., Schwartz K., Coumel P., Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001, 103:89-95.
28. W. Shimizu, M. Horie, S. Ohno, K. Takenaka, M. Yamaguchi, M. Shimizu, T. Washizuka, Y. Aizawa, K. Nakamura, T. Ohe, T. Aiba, Y. Miyamoto, Y. Yoshimasa, J.A. Towbin, S.G. Priori, S. Kamakura, Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J. Am. Coll. Cardiol. (2004) 117-125.
29. Thomas D., Khalil M., Alter M., Schweizer P.A., Karle C.A., Wimmer A.B., Licka M., Katus H.A., Koenen M., Ulmer H.E., Zehelein J. Biophysical characterization of KCNQ1 P320 mutations linked to long QT syndrome 1. J. Mol. Cell. Cardiol. 2010, 48:230-237.
30. Aidery P., Kisselbach J., Schweizer P.A., Becker R., Katus H.A., Thomas D. Biophysical properties of mutant KCNQ1 S277L channels linked to hereditary long QT syndrome with phenotypic variability. Biochim. Biophys. Acta 1812, 2011:488-494.
31. Nagaoka I., Shimizu W., Itoh H., Yamamoto S., Sakaguchi T., Oka Y., Tsuji K., Ashihara T., Ito M., Yoshida H., Ohno S., Makiyama T., Miyamoto Y., Noda T., Kamakura S., Akao M., Horie M. Mutation site dependent variability of cardiac events in Japanese LQT2 form of congenital long-QT syndrome. Circ. J. 2008, 72:694-699.
32. Shimizu W., Moss A.J., Wilde A.A., Towbin J.A., Ackerman M.J., January C.T., Tester D.J., Zareba W., Robinson J.L., Qi M., Vincent G.M., Kaufman E.S., Hofman N., Noda T., Kamakura S., Miyamoto Y., Shah S., Amin V., Goldenberg I., Andrews M.L., McNitt S. Genotype-phenotype aspects of type 2 long QT syndrome. J. Am. Coll. Cardiol. 2009, 54:2052-2062.